# Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

> **NCT04262856** · PHASE2 · COMPLETED · sponsor: **Arcus Biosciences, Inc.** · enrollment: 151 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
- Lung Cancer

## Interventions

- **DRUG:** Domvanalimab
- **DRUG:** Etrumadenant
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT04262856
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-28
- **Primary completion:** 2025-06-05
- **Final completion:** 2025-07-09
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2025-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262856, "Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04262856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*